Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosclevudine Alafenamide SCHEMBL21577294 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL19825437 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL17859274 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL29462222 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL24737195 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL17859276 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL24723318 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| Fosclevudine Alafenamide SCHEMBL17859295 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| SCHEMBL23720991 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 | |
| SCHEMBL25574812 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9BTN3A1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210395290-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-20200299320-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
| US-10683319-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, HPRT1 | CYP3A4 652/4885CYP2C9 771/4885BTN3A1 3338/4885 |
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, HPRT1 | CYP3A4 652/4885CYP2C9 771/4885BTN3A1 3338/4885 |
| US-10683319-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, MTAP | CYP3A4 1262/4885CYP2C9 2080/4885BTN3A1 2858/4885 |
| US-20200299320-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, MTAP | CYP3A4 1262/4885CYP2C9 2080/4885BTN3A1 2858/4885 |
| US-20210395290-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, MTAP | CYP3A4 1262/4885CYP2C9 2080/4885BTN3A1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.